{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1653","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"OFA: Upper limit of 95% CI for median OS is not estimable due to sparse events in the data / insufficient number of participants with events.","groupId":"OG000","lowerLimit":"50.6","upperLimit":"NA","value":"65.1"},{"comment":"IBR: Upper limit of 95% CI for median OS is not estimable due to sparse events in the data / insufficient number of participants with events.","groupId":"OG001","lowerLimit":"61.0","upperLimit":"NA","value":"67.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"description":"OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm","dispersionType":"95% Confidence Interval","groups":[{"description":"An anti-CD20 monoclonal antibody\n\nofatumumab: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.\n\nWeek 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)","id":"OG000","title":"Ofatumumab (Arm A)"},{"description":"A Bruton Tyrosine Kinase Inhibitor\n\nibrutinib: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity","id":"OG001","title":"Ibrutinib (Arm B)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up","title":"OS (Overall Survival)","type":"SECONDARY","unitOfMeasure":"months"}